US20050049226A1 - Preparation of (S)-clopidogrel and related compounds - Google Patents

Preparation of (S)-clopidogrel and related compounds Download PDF

Info

Publication number
US20050049226A1
US20050049226A1 US10/963,707 US96370704A US2005049226A1 US 20050049226 A1 US20050049226 A1 US 20050049226A1 US 96370704 A US96370704 A US 96370704A US 2005049226 A1 US2005049226 A1 US 2005049226A1
Authority
US
United States
Prior art keywords
acid
group
enantiomerically enriched
chlorophenyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/963,707
Inventor
Richard Silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shasun Pharma Solutions Inc
Original Assignee
Rhodia Pharma Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodia Pharma Solutions Inc filed Critical Rhodia Pharma Solutions Inc
Priority to US10/963,707 priority Critical patent/US20050049226A1/en
Publication of US20050049226A1 publication Critical patent/US20050049226A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Definitions

  • the present invention relates to a process for enantioselective preparation of (S)-Clopidogrel, a potent platelet aggregation inhibitor, and related compounds. More particularly, the present invention relates to a process for the preparation of (S)-Clopidogrel in high enantioselectivity and yield.
  • (S)-Clopidogrel is used as an antithrombotic agent for treatment of patients with vascular diseases, myocardial infraction and stroke.
  • the present invention employs a novel approach, which does not require enzymatic or classical resolution techniques to obtain a final product having high enantioselectivity (ee).
  • the present invention overcomes the disadvantages of the prior art described above by providing a process, which enables one to obtain an enantiomerically pure or enantiomerically enriched product without the need for laborious procedures and separations.
  • the present invention provides a process for preparing an enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethylamino) (2-chlorophenyl)-acetonitrile intermediate represented by the formula: which is an intermediate in the preparation of an enantiomerically enriched derivative of (S)- ⁇ -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester represented by the formula: the process including the step of:
  • the present invention further provides a process for producing enantiomerically enriched derivative of (S)alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester, represented by the formula: the process including the steps of:
  • the present invention still further provides a process for preparing an enantiomerically enriched (S)- ⁇ , ⁇ -(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile represented by the formula: which is an intermediate in the preparation of enantiomerically enriched (S)- ⁇ -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5-(4H)-acetic acid methyl ester represented by the formula: the process including the step of:
  • the present invention also provides process for producing enantiomerically enriched (S)alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester, represented by the formula:
  • the process includes the steps of:
  • the present invention provides a process for the preparation of (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester (Clopidogrel) and related compounds.
  • the process involves the condensation of 2-chlorobenaldehyde with 2-(2-amioethyl) thiophene to yield the corresponding imine. Reaction of the resulting imine with HCN in the presence of a catalyst yields the corresponding cyano amine with enantiomeric excess (hereinafter ee) in the range of 75 to 85% ee.
  • the present invention does not rely on biocatalysts or classical resolution methods to produce high in the final product. This is achieved by using a catalyst represented by the formula:
  • This catalyst can be prepared by a procedure described in a publication by Petr Vachel and Eric N. Jacobsen, Org. Letters , Vol. 2, No. 6, p.867-870 (2000). This catalyst is sometimes referred to as “Jacobsen non-metallic asymmetric Strecker catalyst.”
  • the resulting amine or its salt i.e., the HCl salt
  • 1,3 dioxolane may be treated with 1,3 dioxolane to yield the corresponding cyano pyrido thiophene.
  • the Clopidogrel may be isolated by treatment of the cyano pyrido thiophene with acid and an alcohol, such as, methanol.
  • the present invention provides a process for preparing an enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethylamino) (2-chlorophenyl)-acetonitrile intermediate represented by the formula: which is an intermediate in the preparation of an enantiomerically enriched derivative of (S)- ⁇ -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester.
  • the ester is represented by the following formula:
  • the process includes the step of contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl) imine represented by the formula: and an HCN source.
  • the contacting step is optionally carried out in the presence of a catalyst represented by the formula:
  • R 1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R 2 is a substituent at the 4 or 5 position of the thiophene ring; each R 1 and R 2 can independently be H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl; and R 3 is a hydrocarbyl group; and R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof; the contacting being at a temperature and length of time sufficient to
  • R 3 is a linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms or any combination thereof.
  • Compounds wherein R 3 is methyl, ethyl or a mixture thereof are preferred.
  • the derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine is prepared by a process including the step of contacting an R 1 substituted derivative of 2-chlorobenzaldehyde and an R 2 substituted derivative of 2-(2-aminoethyl)-thiophene, optionally in the presence of a catalyst, such as, an acid, molecular sieves or a combination thereof, at a temperature and length of time sufficient to produce the derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine.
  • a catalyst such as, an acid, molecular sieves or a combination thereof
  • the process further includes the step of contacting the enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethyl-amino)-(2-chlorophenyl)-acetonitrile and an acid HX, wherein X is the counter anion of the acid.
  • the contacting step is carried out at a temperature and length of time sufficient to produce a salt of the enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenyl-ethylamino)-(2-chlorophenyl)-acetonitrile, which is represented by the formula:
  • the acid HX can be a mineral acid, an organic acid or a mixture thereof.
  • examples of such acids include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof.
  • HCl and HOAc are preferred.
  • the salt of the enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile can be purified by recrystallization from a suitable recrystallizing solvent, such as, hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone or a mixture thereof.
  • a suitable recrystallizing solvent such as, hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone or a mixture thereof.
  • the recrystallizing solvent is a mixture including toluene and isopropanol in a 2:1 ratio by weight.
  • the enantiomerically enriched derivative of (S)- ⁇ , ⁇ -(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, or a salt thereof, and a formaldehyde equivalent are then contacted, optionally in the presence of an acid catalyst, such as, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof.
  • an acid catalyst such as, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof.
  • the contacting is carried out at a temperature and length of time sufficient to produce enantiomerically enriched ⁇ -5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile, which is represented by the formula:
  • the formaldehyde equivalent in the context of the present invention can be formaldehyde, paraformaldehyde, 1,3 dioxolane, formaline, hexamethylenetetraamine or a mixture thereof.
  • a solution of HCN is prepared by adding trimethylsilyl cyanide (TMSCN) (0.59 g, 0.004 mmol) and methanol (0.140 g, 0.004 mmol) to a solution of toluene (5 mL) at 0° C. and stirring for 1 h.
  • TMSCN trimethylsilyl cyanide
  • methanol 0.140 g, 0.004 mmol
  • Imine 3 is added neat to a reaction vessel and catalyst 4a (5 mol %) is added to the reaction vessel.
  • the vessel is cooled to ⁇ 15° C. and the HCN solution mentioned above is added.
  • the reaction is allowed to stir for 15 h.
  • HCl salt 6 is added to a solution of 1,3-dioxane and heated for 3 h at 90° C. for 8 h. The reaction mixture is allowed to cool and then water (20 mL) is added. The resulting solution is extracted with ethyl acetate (3 ⁇ 20 mL). The organics are dried over sodium sulfate, filtered and evaporated to yield clear oil. The title compound is isolated in near quantitative yield (chemical purity 94%).
  • Compound 7 can be transformed to the title compound by any method known in the art for the conversion of a nitrile into the corresponding methyl ester.
  • the process is carried out by condensing 2-chlorobenzaldehyde and 2-aminoethylthipheneto to give the corresponding imine 3.
  • Imine 3 is then treated with a chiral catalyst and HCN at ⁇ 15° C., i.e., under the asymmetric Strecker conditions.
  • the chiral catalyst can be either one of the Jacobsen non-metallic Strecker catalyst 1 c or 1b, which are described in Petr Vachel and Eric N. Jacobsen, Org. Letters , Vol. 2, No. 6, p.867-870 (2000).
  • the Jacobsen non-metallic Strecker catalyst 1 c is referred to herein as catalyst 4a.
  • the Jacobsen non-metallic Strecker catalyst 1b is referred to herein as catalyst 4b.
  • the difference between 4a and 4b is that 4a is soluble in organic solvents, while 4b is bound to polystyrene beads. If 4a is used as a catalyst, an 85% ee of the Strecker adduct is obtained. When 4b is used as a catalyst, an ee of 75% is obtained. If the process is practiced in the absence of the Jacobsen non-metallic Strecker catalysts, a further resolution step would be required.
  • the temperature range for this reaction can be as low as ⁇ 78° C. and as high as 25° C.
  • the temperature at which the reaction is carried out affects the enantiomeric excess obtained in the final product, with the higher temperatures leading to lower selectivities.
  • the resulting Strecker adduct 5 is converted to the corresponding HCl salt 6.
  • the salt of Strecker adduct 5 may be formed by treatment with any inorganic acid, i.e., HBr, hydrogen sulfate, and taurochlorate.
  • HCl salt 6 may be enantiomerically upgraded by recrystallization from a 2:1 toluene: Isopropyl alcohol solution or be carried onto the next step.
  • the HCl salt 6 is converted to cyano thiophene 7. This is accomplished by any of the well-known methods for Pictet-Spengler type reactions (for leading references see: Ohno et al, Chem. Pharm. Bull., 1994, 42, 1676-1678).
  • Compound 5 or 6 can be treated with acid and formaldehyde or formaldehyde equivalent to give the compound 7.
  • Compound 7 can then be converted to Clopidogrel by treatment with methanol in the presence of any suitable acid known in the art.
  • compound 7 can be hydrolyzed to the corresponding carboxylic acid by reagents known for this transformation and then treated with any reagent known to convert carboxylic acids to methyl ester.
  • (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester known as (S)-Clopidogrel, has utility as a platelet aggregation inhibitor and is described as being an antithrombotic agent in patients with vascular diseases, myocardial infraction and stroke.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

A process for producing enantiomerically enriched (S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester, represented by the formula:
Figure US20050049226A1-20050303-C00001
Is provided, wherein R1 and R2 are hydrogens and R3 is methyl (i.e., (S)-Clopidogrel). The process includes the steps of: (a) contacting N-2-chlorobenz-aldehyde-ylidene-1-ethylamine-2 (2-thiophenyl)imine and an HCN source, in the presence of a non-metallic asymmetric Strecker catalyst to form enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile; (b) contacting the enantiomerically enriched (s)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile and a formaldehyde equivalent, in the presence of an acid catalyst to form enantiomerically enriched α-5 (4,5,6,7-tetrahydro[3,2-c] thienopyridyl) (2-chlorobenzyl)-nitrile; and (c) contacting the enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c] thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group to form enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to a process for enantioselective preparation of (S)-Clopidogrel, a potent platelet aggregation inhibitor, and related compounds. More particularly, the present invention relates to a process for the preparation of (S)-Clopidogrel in high enantioselectivity and yield. (S)-Clopidogrel is used as an antithrombotic agent for treatment of patients with vascular diseases, myocardial infraction and stroke.
  • 2. Description of the Prior Art
  • Currently there are two known processes for the preparation of (S)-Clopidogrel. Each of these processes relies on classical resolution or enzymatic techniques to introduce the sole chiral center into the molecule.
  • U.S. Pat. No. 4,847,265 describes a method of preparation of Clopidogrel employing classical resolution techniques.
  • French Patent Applications Nos. 2,530,247 and 2,769,313 describe commercial methods that are currently used to synthesize Clopidogrel.
  • When classical resolution techniques are employed, the following problems must be overcome: (1) a suitable resolving agent must be found; (2) the resolving reagent must be recycled to make the resolution economical; and (3) isolation and racemization of the starting material from the mother liquor must be carried out efficiently to improve the economics and overall yield.
  • The problems with enzymatic resolution techniques are similar to classical resolution techniques in that low yield of the desired enantiomer makes it necessary to isolate and racemize starting material from the mother liquor. An added problem with enzymatic resolution is low volumetric throughput and tedious work up procedures.
  • To overcome these disadvantages of the prior art, laborious procedures and separations would be required to either enrich the racemic product in one or the other enantiomer or to efficiently and completely separate one enantiomer from the other.
  • The present invention employs a novel approach, which does not require enzymatic or classical resolution techniques to obtain a final product having high enantioselectivity (ee).
  • In addition, the present invention overcomes the disadvantages of the prior art described above by providing a process, which enables one to obtain an enantiomerically pure or enantiomerically enriched product without the need for laborious procedures and separations.
    • SUMMARY OF THE INVENTION
  • The present invention provides a process for preparing an enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl)-acetonitrile intermediate represented by the formula:
    Figure US20050049226A1-20050303-C00002
    which is an intermediate in the preparation of an enantiomerically enriched derivative of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester represented by the formula:
    Figure US20050049226A1-20050303-C00003
    the process including the step of:
      • contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl) imine represented by the formula:
        Figure US20050049226A1-20050303-C00004
        and an HCN source, optionally in the presence of a catalyst represented by the formula:
        Figure US20050049226A1-20050303-C00005
      • wherein R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring;
      • wherein each R1 and R2 can independently be H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl;
      • wherein R3 is a hydrocarbyl group; and
      • wherein R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof; the contacting being at a temperature and length of time sufficient to form the enantiomerically enriched derivative of (S)-alpha-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile.
  • The present invention further provides a process for producing enantiomerically enriched derivative of (S)alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester, represented by the formula:
    Figure US20050049226A1-20050303-C00006
    the process including the steps of:
      • (a) contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl)imine represented by the formula:
        Figure US20050049226A1-20050303-C00007
        and an HCN source, optionally in the presence of a catalyst represented by the formula:
        Figure US20050049226A1-20050303-C00008
        wherein the contacting is carried out at a temperature and length of time sufficient to form a derivative of enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, represented by the formula:
        Figure US20050049226A1-20050303-C00009
      • (b) contacting the derivative of enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile and a formaldehyde equivalent, optionally in the presence of a catalyst, wherein the contacting is carried out at a temperature and length of time sufficient to form a derivative of enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile, represented by the formula:
        Figure US20050049226A1-20050303-C00010
      • (c) contacting the derivative of enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group at a temperature and length of time sufficient to form a derivative of an enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid represented by the formula:
        Figure US20050049226A1-20050303-C00011
      • wherein R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring; wherein each R1 and R2 can independently be H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl;
      • wherein R3 is a hydrocarbyl group; and
      • wherein R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof.
  • The present invention still further provides a process for preparing an enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile represented by the formula:
    Figure US20050049226A1-20050303-C00012
    which is an intermediate in the preparation of enantiomerically enriched (S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5-(4H)-acetic acid methyl ester represented by the formula:
    Figure US20050049226A1-20050303-C00013
    the process including the step of:
      • contacting N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine represented by the formula:
        Figure US20050049226A1-20050303-C00014
        and an HCN source in the presence of a catalyst represented by the formula:
        Figure US20050049226A1-20050303-C00015
      • wherein R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads and a mixture thereof, the contacting being at a temperature and length of time sufficient to form the enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile.
  • The present invention also provides process for producing enantiomerically enriched (S)alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester, represented by the formula:
    Figure US20050049226A1-20050303-C00016
  • The process includes the steps of:
      • (a) contacting N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl)imine represented by the formula:
        Figure US20050049226A1-20050303-C00017
        and an HCN source, optionally in the presence of a catalyst represented by the formula:
        Figure US20050049226A1-20050303-C00018
      • wherein R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof, wherein the contacting is carried out at a temperature and length of time sufficient to form an enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, represented by the formula:
        Figure US20050049226A1-20050303-C00019
      • (b) contacting the enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile and a formaldehyde equivalent, optionally in the presence of a catalyst, wherein the contacting is carried out at a temperature and length of time sufficient to form enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile, represented by the formula:
        Figure US20050049226A1-20050303-C00020
      • (c) contacting the enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group at a temperature and length of time sufficient to form an enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid represented by the formula:
        Figure US20050049226A1-20050303-C00021
        wherein R3 is a hydrocarbyl group.
  • The advantages of the current process include the production of (S)-Clopidogrel in high ee, high yield and with good volumetric throughput without the need to resort to enzymatic or classical resolution techniques.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides a process for the preparation of (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester (Clopidogrel) and related compounds.
  • The process involves the condensation of 2-chlorobenaldehyde with 2-(2-amioethyl) thiophene to yield the corresponding imine. Reaction of the resulting imine with HCN in the presence of a catalyst yields the corresponding cyano amine with enantiomeric excess (hereinafter ee) in the range of 75 to 85% ee.
  • The present invention does not rely on biocatalysts or classical resolution methods to produce high in the final product. This is achieved by using a catalyst represented by the formula:
    Figure US20050049226A1-20050303-C00022
  • This catalyst can be prepared by a procedure described in a publication by Petr Vachel and Eric N. Jacobsen, Org. Letters, Vol. 2, No. 6, p.867-870 (2000). This catalyst is sometimes referred to as “Jacobsen non-metallic asymmetric Strecker catalyst.”
  • The resulting amine or its salt, i.e., the HCl salt, may be treated with 1,3 dioxolane to yield the corresponding cyano pyrido thiophene. Then, the Clopidogrel may be isolated by treatment of the cyano pyrido thiophene with acid and an alcohol, such as, methanol.
  • The present invention provides a process for preparing an enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl)-acetonitrile intermediate represented by the formula:
    Figure US20050049226A1-20050303-C00023
    which is an intermediate in the preparation of an enantiomerically enriched derivative of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetic acid hydrocarbyl ester.
  • The ester is represented by the following formula:
    Figure US20050049226A1-20050303-C00024
  • The process includes the step of contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl) imine represented by the formula:
    Figure US20050049226A1-20050303-C00025
    and an HCN source. The contacting step is optionally carried out in the presence of a catalyst represented by the formula:
    Figure US20050049226A1-20050303-C00026
  • In the compounds described above, R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring; each R1 and R2 can independently be H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl; and R3 is a hydrocarbyl group; and R can be phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof; the contacting being at a temperature and length of time sufficient to form the enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile.
  • Preferably, R3 is a linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms or any combination thereof. Compounds wherein R3 is methyl, ethyl or a mixture thereof are preferred.
  • The derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine is prepared by a process including the step of contacting an R1 substituted derivative of 2-chlorobenzaldehyde and an R2 substituted derivative of 2-(2-aminoethyl)-thiophene, optionally in the presence of a catalyst, such as, an acid, molecular sieves or a combination thereof, at a temperature and length of time sufficient to produce the derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine.
  • The process further includes the step of contacting the enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethyl-amino)-(2-chlorophenyl)-acetonitrile and an acid HX, wherein X is the counter anion of the acid. The contacting step is carried out at a temperature and length of time sufficient to produce a salt of the enantiomerically enriched derivative of (S)-α,α-(2-thiophenyl-ethylamino)-(2-chlorophenyl)-acetonitrile, which is represented by the formula:
    Figure US20050049226A1-20050303-C00027
  • The acid HX can be a mineral acid, an organic acid or a mixture thereof. Examples of such acids include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof. HCl and HOAc are preferred.
  • The salt of the enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile can be purified by recrystallization from a suitable recrystallizing solvent, such as, hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone or a mixture thereof.
  • Preferably, the recrystallizing solvent is a mixture including toluene and isopropanol in a 2:1 ratio by weight.
  • The enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, or a salt thereof, and a formaldehyde equivalent, are then contacted, optionally in the presence of an acid catalyst, such as, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid or a mixture thereof. The contacting is carried out at a temperature and length of time sufficient to produce enantiomerically enriched α-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile, which is represented by the formula:
    Figure US20050049226A1-20050303-C00028
      • wherein R1 and R2 are as previously described herein above.
  • The formaldehyde equivalent in the context of the present invention can be formaldehyde, paraformaldehyde, 1,3 dioxolane, formaline, hexamethylenetetraamine or a mixture thereof.
  • When R1 and R2 are hydrogens, and R3 is methyl, the process of the present invention produces (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester, which is also known as (S)-Clopidogrel.
  • The various aspects of the present invention are described in the following examples, which are only illustrative and therefore, should not be construed as limiting of the scope of the invention.
    • EXAMPLE 1
  • Figure US20050049226A1-20050303-C00029
    N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl) amine (3):
  • To a solution of hexane (20 mL), at 0° C., was added 4 Å molecular sieves (1 g), 2-chlorobenaldehyde (0.55 g, 0.0048 mmol), and 2(2-aminoethyl) thiophene. The solution was allowed to stir for 1 h, filtered, and evaporated to yield the title compound. The title compound was used in the next step without further purification.
    Figure US20050049226A1-20050303-C00030
    (S)-2-chloro-alpha-[(phenylsulfonyl)oxy]benzeneaceto nitrile(3):
  • A solution of HCN is prepared by adding trimethylsilyl cyanide (TMSCN) (0.59 g, 0.004 mmol) and methanol (0.140 g, 0.004 mmol) to a solution of toluene (5 mL) at 0° C. and stirring for 1 h. Imine 3 is added neat to a reaction vessel and catalyst 4a (5 mol %) is added to the reaction vessel. The vessel is cooled to −15° C. and the HCN solution mentioned above is added. The reaction is allowed to stir for 15 h.
  • The completion of the reaction is determined by monitoring the reaction with TLC (10% ethyl acetate in hexane). Amine 5 can be isolated as on oil in near quantitative yield (95% chemical purity) and in 85% ee by evaporation of the reaction solvent, or it may be converted to the corresponding HCl salt 6 by treatment with 1 M HCl in acetic acid (2 equiv). The oil is not purified. Recrystallization of HCl salt 6 may be accomplished by heating in a solution of toluene: isopropyl alcohol (2:1 ratio).
    Figure US20050049226A1-20050303-C00031
    Alpha-5 (4,5,6,7-tetrahydro (3,2-c) thienopyridyl)(2-chlorobenzyl)-nitrile (7):
  • HCl salt 6 is added to a solution of 1,3-dioxane and heated for 3 h at 90° C. for 8 h. The reaction mixture is allowed to cool and then water (20 mL) is added. The resulting solution is extracted with ethyl acetate (3×20 mL). The organics are dried over sodium sulfate, filtered and evaporated to yield clear oil. The title compound is isolated in near quantitative yield (chemical purity 94%).
  • (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester (Clopidogrel):
  • Compound 7 can be transformed to the title compound by any method known in the art for the conversion of a nitrile into the corresponding methyl ester.
  • The process is carried out by condensing 2-chlorobenzaldehyde and 2-aminoethylthipheneto to give the corresponding imine 3. Imine 3 is then treated with a chiral catalyst and HCN at −15° C., i.e., under the asymmetric Strecker conditions.
  • The chiral catalyst can be either one of the Jacobsen non-metallic Strecker catalyst 1 c or 1b, which are described in Petr Vachel and Eric N. Jacobsen, Org. Letters, Vol. 2, No. 6, p.867-870 (2000). The Jacobsen non-metallic Strecker catalyst 1 c is referred to herein as catalyst 4a. The Jacobsen non-metallic Strecker catalyst 1b is referred to herein as catalyst 4b. The difference between 4a and 4b is that 4a is soluble in organic solvents, while 4b is bound to polystyrene beads. If 4a is used as a catalyst, an 85% ee of the Strecker adduct is obtained. When 4b is used as a catalyst, an ee of 75% is obtained. If the process is practiced in the absence of the Jacobsen non-metallic Strecker catalysts, a further resolution step would be required.
  • The temperature range for this reaction can be as low as −78° C. and as high as 25° C. The temperature at which the reaction is carried out affects the enantiomeric excess obtained in the final product, with the higher temperatures leading to lower selectivities.
  • When the asymmetric Strecker reaction is complete, the resulting Strecker adduct 5 is converted to the corresponding HCl salt 6. The salt of Strecker adduct 5 may be formed by treatment with any inorganic acid, i.e., HBr, hydrogen sulfate, and taurochlorate. HCl salt 6 may be enantiomerically upgraded by recrystallization from a 2:1 toluene: Isopropyl alcohol solution or be carried onto the next step. The HCl salt 6 is converted to cyano thiophene 7. This is accomplished by any of the well-known methods for Pictet-Spengler type reactions (for leading references see: Ohno et al, Chem. Pharm. Bull., 1994, 42, 1676-1678).
  • Compound 5 or 6 can be treated with acid and formaldehyde or formaldehyde equivalent to give the compound 7. Compound 7 can then be converted to Clopidogrel by treatment with methanol in the presence of any suitable acid known in the art. Similarly, compound 7 can be hydrolyzed to the corresponding carboxylic acid by reagents known for this transformation and then treated with any reagent known to convert carboxylic acids to methyl ester.
  • (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5 (4H)-acetic acid methyl ester, known as (S)-Clopidogrel, has utility as a platelet aggregation inhibitor and is described as being an antithrombotic agent in patients with vascular diseases, myocardial infraction and stroke.
  • The present invention has been described with particular reference to the preferred embodiments. It should be understood that variations and modifications thereof can be devised by those skilled in the art without departing from the spirit and scope of the present invention. Accordingly, the present invention embraces all such alternatives, modifications and variations that fall within the scope of the appended claims.

Claims (34)

1. A process comprising the step of:
contacting a derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2 (2-thiophenyl) imine represented by the formula:
Figure US20050049226A1-20050303-C00032
and an HCN source, optionally in the presence of a catalyst represented by the formula:
Figure US20050049226A1-20050303-C00033
wherein R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring; wherein each R1 and R2 is independently selected from the group consisting of: H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl;
wherein R3 is a hydrocarbyl group; and
wherein R is selected from the group consisting of: phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof; said contacting being at a temperature and length of time sufficient to form said enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile.
2. The process of claim 1, wherein said derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine is prepared by a process comprising the step of contacting an R1 substituted derivative of 2-chlorobenzaldehyde and an R2 substituted derivative of 2-(2-aminoethyl)-thiophene, optionally in the presence of a catalyst, at a temperature and length of time sufficient to produce said derivative of N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine.
3. The process of claim 2, wherein said catalyst is selected from the group consisting of: an acid, molecular sieves, and a combination thereof.
4. The process of claim 1, further comprising the step of contacting said enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethyl-amino)-(2-chlorophenyl)-acetonitrile and an acid HX, wherein X is the counter anion of said acid, at a temperature and length of time sufficient to produce a salt of said enantiomerically enriched derivative of (S)-α,α-(2-thiophenyl-ethylamino)-(2-chlorophenyl)-acetonitrile, said salt being represented by the formula:
Figure US20050049226A1-20050303-C00034
5. The process of claim 4, wherein said acid HX is selected from the group consisting of: mineral acid, organic acid, and a mixture thereof.
6. The process of claim 4, wherein said acid is selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid and a mixture thereof.
7. The process of claim 4, wherein said acid is selected from the group consisting of: HCl, HOAc, and a mixture thereof.
8. The process of claim 4, further comprising the step of:
recrystallizing said salt of said enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile from a recrystallizing solvent.
9. The process of claim 8, wherein said solvent is selected from the group consisting of: hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone and a mixture thereof.
10. The process of claim 8, wherein said recrystallizing solvent is a mixture comprising toluene and isopropanol in a 2:1 ratio by weight.
11. The process of claim 4, further comprising the step of:
contacting said enantiomerically enriched derivative of (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, or a salt thereof, and a formaldehyde equivalent, optionally in the presence of a catalyst, at a temperature and length of time sufficient to produce enantiomerically enriched α-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile represented by the formula:
Figure US20050049226A1-20050303-C00035
12. The process of claim 11, wherein said formaldehyde equivalent is selected from the group consisting of: formaldehyde, paraformaldehyde, formaline, hexamethylenetetraamine, 1,3 dioxolane and a mixture thereof.
13. The process of claim 11, wherein said catalyst is an acid.
14. The process of claim 13, wherein said acid is selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid and a mixture thereof.
15. The process of claim 11, wherein said enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile salt is the hydrochloride salt thereof.
16. The process of claim 1, wherein R3 is selected from the group consisting of: a linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms and any combination thereof.
17. The process of claim 11, further comprising:
contacting said derivative of enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group at a temperature and length of time sufficient to form a derivative of an enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid represented by the formula:
Figure US20050049226A1-20050303-C00036
wherein R1 is a substituent at the 3, 4, 5 or 6 position of the chlorophenyl ring and R2 is a substituent at the 4 or 5 position of the thiophene ring; wherein each R1 and R2 is independently selected from the group consisting of: H, linear, branched or cyclic alkyl of 1 to 22 carbon atoms, aryl of 6 to 22 carbon atoms, aralkyl of 7 to 22 carbon atoms, alkylaryl of 7 to 22 carbon atoms, halogen, cyano, nitro, amido, carbamato, imido, alkoxy, aryloxy, acyl, alkoxycarbonyl and trifluoromethyl;
wherein R3 is a hydrocarbyl group; and
wherein R is selected from the group consisting of: phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads, and a mixture thereof.
18-20. (canceled)
21. A process comprising the step of:
contacting N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine represented by the formula:
Figure US20050049226A1-20050303-C00037
and an HCN source in the presence of a catalyst represented by the formula:
Figure US20050049226A1-20050303-C00038
wherein R is selected from the group consisting of: phenyl, tolyl, xylyl, naphthyl, heteroaryl, amido, imido, carbamato, polystyrene beads and a mixture thereof, said contacting being at a temperature and length of time sufficient to form said enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile.
22. The process of claim 21, wherein said N-2-chlorobenz-aldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine is prepared by a process comprising the step of contacting 2-chlorobenzaldehyde and 2-(2-aminoethyl)-thiophene, optionally in the presence of a catalyst, at a temperature and length of time sufficient to produce said N-2-chlorobenzaldehydeylidene-1-ethylamine-2-(2-thiophenyl)-imine.
23. The process of claim 22, wherein said catalyst is selected from the group consisting of: an acid, molecular sieves, and a combination thereof.
24. The process of claim 21, further comprising the step of:
contacting said enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile and an acid HX, wherein X is the counter anion of said acid, at a temperature and length of time sufficient to produce a salt of said enantiomerically enriched (S)-α,α-(2-thiophenyl-ethylamino)-(2-chlorophenyl)-acetonitrile, said salt being represented by the formula:
Figure US20050049226A1-20050303-C00039
25. The process of claim 24, wherein said acid HX is selected from the group consisting of: mineral acid, organic acid, and a mixture thereof.
26. The process of claim 24, wherein said acid is selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid and a mixture thereof.
27. The process of claim 24, wherein said acid is selected from the group consisting of: HCl, HOAc, and a mixture thereof.
28. The process of claim 24, further comprising the step of:
recrystallizing said salt of enantiomerically enriched (S)-α,α-(2-thiophenylethylamino)-(2-chlorophenyl)-acetonitrile from a recrystallizing solvent.
29. The process of claim 28, wherein said solvent is selected from the group consisting of: hexanes, toluene, methanol, ethanol, isopropanol, methylene chloride, tetrahydrofurane, ether, ethyl acetate, acetone and a mixture thereof.
30. The process of claim 28, wherein said recrystallizing solvent is a mixture comprising toluene and isopropanol in a 2:1 ratio by weight.
31. The process of claim 24, further comprising the step of:
contacting said enantiomerically enriched (S)-α,α-(2-thiophenylethylamino) (2-chlorophenyl) acetonitrile, or a salt thereof, and a formaldehyde equivalent, optionally in the presence of a catalyst, at a temperature and length of time sufficient to produce enantiomerically enriched α-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile represented by the formula:
Figure US20050049226A1-20050303-C00040
32. The process of claim 31, wherein said formaldehyde equivalent is selected from the group consisting of: formaldehyde, paraformaldehyde, formaline, hexamethylenetetraamine, 1,3 dioxolane and a mixture thereof.
33. The process of claim 31, wherein said catalyst is an acid.
34. The process of claim 33, wherein said acid is selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, trichloroacetic acid, trifluoroacetic acid, trichloromethanesulfonic acid, trifluoromethanesulfonic acid and a mixture thereof.
35. The process of claim 31, further comprising:
contacting said enantiomerically enriched α-5(4,5,6,7-tetrahydro[3,2-c]thienopyridyl) (2-chlorobenzyl)-nitrile and a reagent capable of converting a cyano group into an ester group at a temperature and length of time sufficient to form an enantiomerically enriched hydrocarbyl ester of (S)-α-(2-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)-acetic acid represented by the formula:
Figure US20050049226A1-20050303-C00041
wherein R3 is a hydrocarbyl group.
36-38. (canceled)
US10/963,707 2003-04-23 2004-10-13 Preparation of (S)-clopidogrel and related compounds Abandoned US20050049226A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/963,707 US20050049226A1 (en) 2003-04-23 2004-10-13 Preparation of (S)-clopidogrel and related compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/421,564 US6858734B2 (en) 2003-04-23 2003-04-23 Preparation of (S)-Clopidogrel and related compounds
US10/963,707 US20050049226A1 (en) 2003-04-23 2004-10-13 Preparation of (S)-clopidogrel and related compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/421,564 Division US6858734B2 (en) 2003-04-23 2003-04-23 Preparation of (S)-Clopidogrel and related compounds

Publications (1)

Publication Number Publication Date
US20050049226A1 true US20050049226A1 (en) 2005-03-03

Family

ID=33298706

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/421,564 Expired - Fee Related US6858734B2 (en) 2003-04-23 2003-04-23 Preparation of (S)-Clopidogrel and related compounds
US10/963,707 Abandoned US20050049226A1 (en) 2003-04-23 2004-10-13 Preparation of (S)-clopidogrel and related compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/421,564 Expired - Fee Related US6858734B2 (en) 2003-04-23 2003-04-23 Preparation of (S)-Clopidogrel and related compounds

Country Status (3)

Country Link
US (2) US6858734B2 (en)
TW (1) TW200503688A (en)
WO (1) WO2004094374A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134600A1 (en) 2007-04-27 2008-11-06 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US8835407B2 (en) 2009-05-13 2014-09-16 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100681512B1 (en) 2005-03-08 2007-02-09 주식회사 한서켐 A novel intermediate of clopidogrel and the manufacturing process by using it
JP2008540546A (en) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド Nanoparticulate clopidogrel formulation
EA200800041A1 (en) * 2005-06-13 2008-04-28 Элан Фарма Интернэшнл Лтд. COMPOSITIONS WITH NAPPON HEATING NANOPARTICLES CONTAINING THE COMBINATION OF A NECK WARMING AND ASPIRIN
CN100463909C (en) * 2005-09-08 2009-02-25 浙江华海药业股份有限公司 Synthesis method of thienotetrahydropyridine acetonitrile
DE102006028451A1 (en) * 2006-06-21 2008-01-10 Studiengesellschaft Kohle Mbh Process for the preparation of N-acyl-α-aminonitriles
EP1931682A2 (en) * 2006-08-03 2008-06-18 Teva Pharmaceutical Industries Ltd. Process for preparing clopidogrel bisulphate
KR100990949B1 (en) * 2008-06-09 2010-10-29 엔자이텍 주식회사 Method for Preparing Clopidogrel and Derivatives Thereof
CN102241690B (en) 2010-05-13 2015-08-12 天津药物研究院 Thienopyridine ester derivative, the Preparation Method And The Use of one class nitrile group-containing
CN102432626B (en) * 2011-11-14 2014-07-02 连云港宏业化工有限公司 Synthesis method of 4,5,6,7-tetrahydrothiophene[3,2-c] pyridine hydrochloride
CN104379589A (en) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 Prodrugs of anti-platelet agents
WO2023012479A1 (en) 2021-08-03 2023-02-09 Liqmeds Worldwide Limited An oral pharmaceutical solution of clopidogrel

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (en) * 1987-02-17 1992-01-24 Sanofi Sa ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
HU225503B1 (en) * 1997-05-13 2007-01-29 Sanofi Aventis Novel 2-(2-halophenyl)-2-(2-(2-thienyl)-ethylamino)-acetamides and process for producing them

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134600A1 (en) 2007-04-27 2008-11-06 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US20100292268A1 (en) * 2007-04-27 2010-11-18 Cydex Pharmaceuticals, Inc. Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use
US8343995B2 (en) 2007-04-27 2013-01-01 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US8853236B2 (en) 2007-04-27 2014-10-07 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US9125945B2 (en) 2007-04-27 2015-09-08 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US9623045B2 (en) 2007-04-27 2017-04-18 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US10034947B2 (en) 2007-04-27 2018-07-31 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US10512697B2 (en) 2007-04-27 2019-12-24 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
EP3766493A1 (en) 2007-04-27 2021-01-20 CyDex Pharmaceuticals, Inc. Method for improving the stability of clopidogrel using sulfoalkyl ether cyclodextrin
US8835407B2 (en) 2009-05-13 2014-09-16 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
US9399067B2 (en) 2009-05-13 2016-07-26 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
US10111863B2 (en) 2009-05-13 2018-10-30 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same

Also Published As

Publication number Publication date
TW200503688A (en) 2005-02-01
WO2004094374A3 (en) 2006-08-24
US20040214878A1 (en) 2004-10-28
US6858734B2 (en) 2005-02-22
WO2004094374A2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
KR100990949B1 (en) Method for Preparing Clopidogrel and Derivatives Thereof
US6858734B2 (en) Preparation of (S)-Clopidogrel and related compounds
JP4264437B2 (en) Hydroxyacetic acid ester derivatives, their production and use as synthetic intermediates
US7629465B2 (en) Industrial process for preparation of Clopidogrel hydrogen sulphate
CA2436323C (en) Process for preparing clopidogrel
US6180793B1 (en) Process for the preparation of a pharmacologically active substance
US6215005B1 (en) Intermediates and process for the preparation thereof
EP1669359B1 (en) A process for the preparation of olanzapine and an intermediate therefor
US20050049415A1 (en) Process for preparing enantiomerically pure alpha phenyl-alpha (6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)-acetic acid derivatives
WO2006086921A1 (en) A process for the preparation of clopidogrel
EP1501838B1 (en) A process for the preparation of clopidogrel
US6495691B1 (en) Process for the preparation of tetrahydrothieno[3,2-c]pyridine derivatives
US20120123124A1 (en) Manufacturing process for Tadalafil from racemic or L-tryptophan
US5821369A (en) Racemisation process
CA2218654C (en) Synthesis of (s)-3-(2-thienylthio) butyric acid and analogs
EP2107061A1 (en) Process for the preparation of optically enriched clopidogrel
US6639095B1 (en) Process for preparing optically active α-hydroxy acids and derivatives thereof
KR100681512B1 (en) A novel intermediate of clopidogrel and the manufacturing process by using it
US7060831B2 (en) Process for the preparation of tetrahydrothieno[3,2-c] pyridine derivatives
WO2009080469A1 (en) Process for the preparation of clopidogrel bisulphate form i
KR101088859B1 (en) Method for Preparing Clopidogrel and Derivatives Thereof
EP1980563A1 (en) Procedure for the preparation of methyl (+)-(S)-Alpha-(O-chlorophenyl)-6,7-dihydrothieno-[3,2-C]pyridine-5(4H) acetate
JP2001199980A (en) Method of manufacturing for optically active homocysteine thiolactone salt
KR20080034611A (en) Method for preparing clopidogrel hydrogensulfate

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION